Akcea Therapeutics Steps Up Commercialization Efforts In Europe
With one rare disease drug already available in Europe, and a second imminent, Akcea’s CEO outlined in a Scrip interview the European plans for this still-youthful US biotech.
You may also be interested in...
Akcea terminates top three execs while praising their accomplishments in building up the Ionis spinout. Stock finished the trading day down nearly 20%.
Akcea’s Waylivra, Portola’s Ondexxya, BioMarin’s Palynziq, AbbVie’s Skyrizi and Pfizer’s Lorviqua are among new drugs to receive a positive opinion from the EU’s CHMP at its latest monthly meeting.
Despite complete response letter for Akcea's Waylivra, RNA therapeutics may have regulatory pathway to approval for lipid disorders.